A5072952875- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Testicular diseases and treatments
- Prostate Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Cancer-related molecular mechanisms research
- Multiple Myeloma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Estrogen and related hormone effects
- NF-κB Signaling Pathways
- RNA modifications and cancer
- Renal cell carcinoma treatment
- Case Reports on Hematomas
- Venous Thromboembolism Diagnosis and Management
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Inflammatory mediators and NSAID effects
- Vibrio bacteria research studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
Memorial Sloan Kettering Cancer Center
2024-2025
Kettering University
2025
Dana-Farber Cancer Institute
2017-2024
Harvard University
2019-2024
The University of Melbourne
2021-2024
Cabrini Hospital
2021-2023
Boston University
2023
Eastern Health
2020-2023
Peter MacCallum Cancer Centre
2023
Monash University
2021-2023
5005 Background: 177 Lu-PSMA-617, a PSMA-directed, radionuclide therapy improves progression free survival (PFS) and overall (OS) in patients (pts) with mCRPC. Although many pts benefit from treatment, approximately third have primary resistance, median PFS is 5.1 months all inevitably relapse. Poly (ADP-ribose) polymerase (PARP) implicated repairing radiation-induced DNA single-strand breaks (SSBs). The potent PARP inhibitor (PARPi) olaparib results the conversion of SSBs to lethal...
<h3>Importance</h3> Approximately 50% of the risk for development testicular germ cell tumors (TGCTs) is estimated to be heritable, but no mendelian TGCT predisposition genes have yet been identified. It hypothesized that inherited pathogenic DNA repair gene (DRG) alterations may drive susceptibility TGCTs. <h3>Objective</h3> To systematically evaluate enrichment germline variants in cancer DRGs patients with TGCTs vs healthy controls. <h3>Design, Setting, and Participants</h3> A...
The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors chemotherapy benefit are undefined.Whole transcriptomic profiling was performed primary PC tissue obtained from patients enrolled prior to systemic therapy. We adopted an priori analytical plan test defined...
•Synchronous metastatic CSPC is associated with lower AR activity than metachronous disease.•Patients synchronous derive a greater benefit to combination plus non AR-based therapy.•Clinical and biologic differences between metastasis are most prominent in low-volume disease. BackgroundMetastatic castration-sensitive prostate cancer (mCSPC) commonly classified into high- subgroups which have demonstrated differential biology, prognosis, response therapy. Timing of has similarly clinical...
Abstract Background Prostate cancer (PCa) is a clinically heterogeneous disease. The creation of an expression‐based subtyping model based on prostate‐specific biological processes was sought. Methods Unsupervised machine learning gene expression profiles from prospectively collected primary prostate tumors (training, n = 32,000; evaluation, 68,547) used to create classifier (PSC) basal versus luminal cell patterns and other signatures relevant PCa biology. Subtype molecular pathways...
Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication change advanced cancer, which defines a wide spectrum disease from high-risk localised to metastatic, is unknown.
We posit the existence of a paracrine/autocrine negative feedback loop, mediated by mineralocorticoid receptor (MR), regulating aldosterone secretion. To assess this hypothesis, we asked whether altering MR activity in zona glomerulosa (ZG) cells affects production. end, studied ex vivo ZG isolated from male Wistar rats fed chow containing either high (1.6% Na + (HS)) or low (0.03% (LS)) amount sodium. Western blot analyses demonstrated that was present both and fasciculata/zona reticularis...
Abstract Background Characterization of markers both immune suppression and activation may provide more prognostic information than assessment single in localized prostate cancer. We therefore sought to determine the association between CD8 PD‐L1 expression tumors biochemical recurrence (BCR) metastasis‐free survival (MFS). Methods Tissue microarrays were constructed on 109 men undergoing radical prostatectomy (RP) for cancer at Dana–Farber Cancer Institute 1991 2008. Fluorescence...
Background There is limited experience regarding the safety and efficacy of checkpoint inhibitors (CPI) in patients with autoimmune disorders (AD) advanced urological cancers as they are generally excluded from clinical trials due to risk exacerbations. Methods This multicenter retrospective cohort analysis renal cell cancer (RCC) urothelial (UC) pre-existing AD treated CPI catalogued incidence exacerbations, new immune-related adverse events (irAEs) outcomes. Competing models estimated...
Metastatic and high-risk localized prostate cancer respond to hormone therapy but outcomes vary. Following a pre-specified statistical plan, we used Cox models adjusted for clinical variables test associations with survival of multi-gene expression-based classifiers from 781 patients randomized androgen deprivation or without abiraterone in the STAMPEDE trial. Decipher score was strongly prognostic (p<2×10-5) identified clinically-relevant differences absolute benefit, especially cancers. In...
Outcomes of testicular germ cell tumors (TGCT), which are the most common malignancies in adolescents and young adult males, paradoxical; although highly curable with platinum based chemotherapy, cancer is also cause highest number years life lost any malignancy. Major barriers to research aiming uncover novel therapeutic approaches for chemotherapy-resistant TGCTs include its relatively low incidence, histologic diversity (seminoma vs multiple non-seminoma histologies), rarity tissue...
5003 Background: Docetaxel (Doce) is effective for metastatic (M1) PC but its effect varied. Combining Doce and hormone therapy can improve overall survival (OS) not appropriate all. We previously reported the mRNA Decipher test predicts benefit from Doce. then used transcriptome-wide data to interrogate differential associations with outcome biologically-relevant pathways. Methods: PTEN inactivation using a described signature (Liu et al JCI, 2021; active score <= 0.3, inactive: >...
Clinical stage I (CSI) nonseminoma (NS) is a disease limited to the testis without metastases. One treatment strategy after orchiectomy adjuvant chemotherapy. Little known about outcome of patients who experience relapse such treatment.Data from 51 with CSI NS experienced bleomycin, etoposide, and cisplatin (BEP) 18 centers/11 countries were collected retrospectively analyzed. Primary outcomes overall progression-free survivals calculated day 1 at first relapse. Secondary time to, at, rate...